Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea Ji Haeng Heo, MS, Karen L.

Slides:

Advertisements

Similar presentations

Cost-Effectiveness of Sensor-Augmented Pump Therapy in Adults with Type 1 Diabetes in the United States Shital Kamble, PhD, Kevin A. Schulman, MD, Shelby.

Advertisements

Value in Health Regional Issues

Performance Assessment of the Juaboso District Office of the National Health Insurance Authority Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Klára Kruntorádová, MSc, Jiří Klimeš,

Examining the Value of Menopausal Symptom Relief Among US Women

Value in Health Regional Issues

Eric Nsiah-Boateng, MPH, Moses Aikins, PhD

The Development of the Romanian Scorecard HTA System

Value in Health Regional Issues

Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.

Value in Health Regional Issues

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Value in Health Regional Issues

From Regulatory Approval to Subsidized Patient Access in the Asia-Pacific Region: A Comparison of Systems Across Australia, China, Japan, Korea, New Zealand,

Impact of the Pharma Economic Act on Diffusion of Innovation and Reduction of Costs in the Hungarian Prescription Drug Market (2007–2010) Rok Hren, PhD,

Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future? Emmanuel Ankrah Odame, MBCHB, MPH Value in.

The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan Kaoru Yamabe, MSc, Puneet K. Singhal,

Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil Ronaldo K.

Value in Health Regional Issues

The Process of Privatization of Health Care Provision in Poland

Boxiong Tang, MD, PhD, Eran Harary, MD, Ricky Kurzman, MSc, Joaquín F

Ernest Attuquaye Quaye, BPharm, MPH, Edward O

The Living with Medicines Questionnaire: Translation and Cultural Adaptation into the Arabic Context Amani Zidan, BScPharm, Ahmed Awaisu, PhD, Sanah.

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Klára Kruntorádová, MSc, Jiří Klimeš,

Value in Health Regional Issues

Cost-Effectiveness of Sertindole among Atypical Antipsychotics in the Treatment of Schizophrenia in South Korea Bo-Ra-Mi Kim, MPH, Tae-Jin Lee, PhD,

Rutger Daems, PhD, Edith Maes, DBA, Christoph Glaetzer, Dipl, Kfm

Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,

Value in Health Regional Issues

Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,

What Is Important During the Selection of Traditional Chinese Medicine (TCM) in a Health Care Reimbursement or Insurance System?” Critical Issues of Assessment.

Assessment of Adverse Events and Quality of Life of Cancer Patients in a Secondary Level Care, Rural Hospital in South India S.K.R. Sowmya, PharmD, Dixon.

Assessment of Effect of Diabetes on Health-Related Quality of Life in Patients with Coronary Artery Disease Using the EQ-5D Questionnaire Bhavik Shah,

Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD

Value in Health Regional Issues

Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD

Patient-Reported Outcomes in Latin America: Implementation in Research and Role in Emerging HTA Systems Randall Winnette, MSc, Victor Zárate, MD, MSc,

Omneya Mohamed, PhD, David H. Kreling, PhD

Patient Utility Measurement for Managing Ureteral Stones: A Modified Standard Gamble Approach Ching-Yuan Fann, PhD, Po-Chien Huang, MD, MS, Amy Ming-Fang.

Onur Baser, MS, PhD, Akif Altinbas, MD, Erdem Baser, MS, M

Analysis of Excess Direct Medical Costs of Vision Impairment in Taiwan

Value in Health Regional Issues

The Economic Impact of Cigarette Smoking on the Poor in Jordan

Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy? Fei-Li.

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project Kyriakos Souliotis, PhD,

Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective Bruno Salgado Riveros,

Drug Utilization Reviews by Community Pharmacists in Japan: Identification of Potential Safety Concerns through the Brown Bag Program Manabu Akazawa,

Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters? Chun-Ru Chien, MD, PhD, Ya-Chen Tina.

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Incidence of Intravenous Medication Errors in a Chinese Hospital

Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan Yoshie Onishi, MS,

Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers Valentina.

Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD

Value in Health Regional Issues

Value in Health Regional Issues

Dossier System as a Practical Tool for Compiling Reimbursement Lists

Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.

Value in Health Regional Issues

Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico

Performance Assessment of the Juaboso District Office of the National Health Insurance Authority Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.

The Drug Reimbursement Decision-Making System in Iran

Social Cost of Substance Abuse in Russia

Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD

Clinical Burden of Invasive Pneumococcal Disease in Selected Developing Countries Namaitijiang Maimaiti, PhD, Zafar Ahmed, PhD, Zaleha Md Isa, PhD, Hasanain.

Victoria I. Ignatyeva, MPH, Johan L

Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.

Value in Health Regional Issues

Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD

Presentation transcript:

Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea Ji Haeng Heo, MS, Karen L. Rascati, PhD, Eui-Kyung Lee, PhD Value in Health Regional Issues Volume 12, Pages 7-19 (May 2017) DOI: 10.1016/j.vhri.2016.07.011 Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 The diagram of Korea National Health Insurance before and after the reference pricing system. Value in Health Regional Issues 2017 12, 7-19DOI: (10.1016/j.vhri.2016.07.011) Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Savings rate on prescription ingredient costs for chemical-level model, therapeutic- level model, and hybrid grouping model under scenarios. Note. Savingsrate(%)=Originalprescriptioningredientcosts($)−Prescriptioningredientcostsunderexpectedscenarios($)Originalprescriptioningredientcosts($) Value in Health Regional Issues 2017 12, 7-19DOI: (10.1016/j.vhri.2016.07.011) Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 Patient co-payments for chemical-level, therapeutic-level, and hybrid grouping models under scenarios. Note. Baseline represents original co-payments for patients before the reference pricing system. Baseline co-pay rate: chemical level, 20.4%; therapeutic level, 20.4%; hybrid grouping model, 22.9%. Value in Health Regional Issues 2017 12, 7-19DOI: (10.1016/j.vhri.2016.07.011) Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 Patient co-payments for chemical-level, therapeutic-level, and hybrid grouping models under scenarios. Note. Baseline represents original co-payments for patients before the reference pricing system. Baseline co-pay rate: chemical level, 20.4%; therapeutic level, 20.4%; hybrid grouping model, 22.9%. Value in Health Regional Issues 2017 12, 7-19DOI: (10.1016/j.vhri.2016.07.011) Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions